V-domain Ig suppressor of T cell activation (VISTA) is a B7 family member that maintains T
cell and myeloid quiescence and is a promising target for combination cancer …

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel negative
checkpoint receptor (NCR) primarily involved in maintaining immune tolerance. It has a role …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by producing
remarkable clinical outcomes for patients with various cancer types. However, only a subset …

VISTA (V-domain Ig suppressor of T cell activation) is a novel immune checkpoint protein
and represents a promising target for cancer immunotherapy. Here, we report the design …

Lymphocyte activation gene 3 (LAG-3) is a negative immune checkpoint that plays a key role
in downregulating the immune response to cancer. Inhibition of LAG-3 interactions allows T …

T-cell immunoglobulin and mucin domain 3 (TIM-3) is a negative immune checkpoint that
represents a promising target for cancer immunotherapy. Although encouraging results have …

Conventional and cancer immunotherapies encompass diverse strategies to address
various cancer types and stages. However, combining these approaches often encounters …

Immune checkpoint inhibitors (ICIs) are used to relieve and refuel anti-tumor immunity by
blocking the interaction, transcription, and translation of co-inhibitory immune checkpoints or …

Tumor cells can evade the innate and adaptive immune systems, which play important roles
in tumor recurrence and metastasis. Malignant tumors that recur after chemotherapy are …

The revolutionary progress in cancer immunotherapy, particularly the advent of immune
checkpoint inhibitors, marks a significant milestone in the fight against malignancies …